Software & Services

Bioclonetics Immunotherapeutics, Inc.

Regulation Crowdfunding campaign information and financial data from SEC filings


Profile

According to their SEC filings, Bioclonetics Immunotherapeutics, Inc. is a Corporation organized in TX on 12-24-2009. They report having 4.00 employees, and revenue in their most recent fiscal year of $0 and $0 the prior year.

Description:
Creating fully human monoclonal antibodies that target and neutralize HIV and other infectious diseases. https://t.co/5tFsbciLiY
Website:
www.bioclonetics.com
Location:
1756 BISON MEADOW LANE
HEATH, TX 75032

Equity Crowdfunding Campaigns

Bioclonetics Immunotherapeutics, Inc. does not currently have any active Reg CF crowdfunding campaigns.

Previous Crowdfunding Offering
Tuesday, November 6, 2018

Bioclonetics Immunotherapeutics, Inc. previously ran a Reg CF crowdfunding campaign to raise a target of $10,000 via StartEngine before a deadline of 11-02-2018. They filed this progress report at the end of the offering: "The amount raised at the time of closing is $265,800." The URL for the offering was https://www.startengine.com/bioclonetics.

Intermediary compensation

According to the SEC filings, StartEngine was compensated as follows for this offering:

"6 percent"

In addition to any direct compensation, Bioclonetics Immunotherapeutics, Inc. reports that StartEngine also received the following financial interest in the offering:

"N/A"
Previous Crowdfunding Offering
Friday, December 1, 2017

Bioclonetics Immunotherapeutics, Inc. previously ran a Reg CF crowdfunding campaign to raise a target of $200,000 via Wefunder before a deadline of 09-29-2017. They filed this progress report at the end of the offering: "The final number is $386,766.00 in investments."

Intermediary compensation

According to the SEC filings, Wefunder was compensated as follows for this offering:

"4.0% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering."

In addition to any direct compensation, Bioclonetics Immunotherapeutics, Inc. reports that Wefunder also received the following financial interest in the offering:

"No"

Financial Information

The following information is taken from SEC filings.

Income Statement Items

Most-Recent Fiscal Year Prior Fiscal Year % Change
Revenue $0 $0 N/A
Cost of Goods Sold $0 $0 N/A
Taxes Paid $0 $0 N/A
Net Income -$217,470 -$95,511 N/A

Balance Sheet Items

Most-Recent Fiscal Year Prior Fiscal Year % Change
Total Assets $183,622 $1,195 15265.9%
Cash & Cash Equivalents $183,622 $1,195 15265.9%
Accounts Receivable $0 $0 N/A
Short-Term Debt $45,285 $32,154 40.8%
Long-Term Debt $386,766 $0 N/A

Complete Reg CF filing activity feed